NCT01235741 - A Study To Examine The Efficacy And Safety Of Pramlintide+Metreleptin In Obese Subjects | Biotech Hunter

Enrollment

213

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2011

Conditions

Obesity

Interventions

DRUG

Pramlintide+Metreleptin

Group A: Subcutaneous Injection once a day (QD): Pramlintide 360 mcg+Metreleptin 5.0 mg for 1 week followed by Pramlintide 360 mcg+Metreleptin 5.0 mg twice a day (BID) for 15 weeks.

DRUG

Placebo

Group B: Subcutaneous Injection-twice a day (BID): Placebo equivalent volumes to active doses.

Trial Locations (18)

Unknown

Research Site, Greenbrae

Research Site, La Jolla

Research Site, Denver

Research Site, Winter Park

Research Site, Chicago

Research Site, Baton Rouge

Research Site, Hyattsville

Research Site, Boston

Research Site, St Louis

Research Site, Butte

Research Site, New York

Research Site, Tulsa

Research Site, Philadelphia

Research Site, Austin

Research Site, Salt Lake City

Research Site, Arlington

Research Site, Norfolk

Research Site, Richmond